



Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Hiroyuki Okuzawa, Representative Director, President and CEO
(Code no.: 4568, Prime Market, Tokyo Stock Exchange)
Please address inquiries to Kentaro Asakura, Corporate Officer,
Head of Corporate Communications Department
Telephone: for media +81-3-6225-1126
for stock market participants +81-3-6225-1125

Daiichi Sankyo Announces Changes to Representative Directors, and Appointments of Directors and Audit & Supervisory Board Members

Tokyo, Japan - (February 26, 2026) – Daiichi Sankyo Company, Limited (hereinafter, the Company) today announced that its Board of Directors has approved changes to its Representative Directors, and appointments of Directors and Audit & Supervisory Board Members as follows.

The Company recognizes that ensuring diversity among directors, including aspects of gender and nationality, is important for strengthening the decision-making and oversight functions of the Board of Directors by incorporating various perspectives and opinions into management. Based on the knowledge, experience, and insights that should be present for the Board of Directors to appropriately exercise its decision-making and oversight functions, and to enhance our corporate value, the Company has made a resolution today at the Board of Directors meeting regarding the appointments of candidates for Directors and Audit & Supervisory Board Members based on the recommendations of the Nominating Committee.

Appointments will be subject to approval at the Company's 21st Ordinary General Shareholders Meeting on June 22, 2026, and formal resolutions at the subsequent board meeting.

1. Change to Representative Director

Reason for change: Expiration of Representative Director's term

Newly Appointed Representative Director

Name	Position (as of February 26, 2026)
Takashi Matsumoto	Director Senior Executive Officer Head of Global HR ¹ Chief Human Resources Officer (CHRO) ¹
Shizuko Ueno	Director Executive Officer Head of Japan Business Unit ² and Head of Medical Affairs Div., Japan Business Unit Special Assignment on Patient Centricity

Retiring Representative Director

Name	Position (as of February 26, 2026)
Sunao Manabe	Representative Director Executive Chairperson

- Current Representative Director, Executive Chairperson, Sunao Manabe, will retire from his position within the Corporate Officer system effective March 31, 2026. He will continue to serve as Representative Director, Executive Chairperson outside the Corporate Officer system. Upon the conclusion of the Company's 21st Ordinary General Shareholders Meeting on June 22, 2026, he will retire as Representative Director, Executive Chairperson due to the expiration of his term. He will be appointed as Senior Adviser of the Company effective June 24, 2026.

2. Changes to Directors

(1) Candidates for Directors

Name		Position (as of June 22, 2026)
Hiroyuki Okuzawa	Reelection	Representative Director, President and CEO
Takashi Matsumoto	Reelection	Representative Director Senior Executive Officer Head of Global HR ¹ CHRO (Chief Human Resources Officer) ¹
Shizuko Ueno	Reelection	Representative Director Senior Executive Officer Head of Japan Business Unit ² Special Assignment on Patient Centricity
Joseph Kenneth Keller	Reelection	Director Head of Global Oncology Business ¹ Head of Oncology Business Unit ¹ (President, Daiichi Sankyo U.S. Holdings, Inc. and President & CEO, Daiichi Sankyo, Inc.)
Stuart Mackey	New election	Director Head of Global Business Development ¹ (Global Head of Business Development, Daiichi Sankyo, Inc.)

Yasuhiro Komatsu	Reelection	Outside Director (Professor Emeritus and Professor (Specially appointed for Quality & Safety Science) at Gunma University Vice president, Itabashi Chuo Medical Center Advisory Board Member, Gunma University Hospital)
Takaaki Nishii	Reelection	Outside Director (Former Director, Representative Executive Officer, President & CEO, Ajinomoto Co., Inc.)
Yo Honma	Reelection	Outside Director (Chief Corporate Advisor of NTT DATA Group Corporation)
Akihiro Watanabe	Reelection	Outside Director (Representative, Akihiro Watanabe CPA Office Chairman of Asia Corporate Finance at Houlihan Lokey)
Reiko Kinoshita	Reelection	Outside Director (Representative Director of Admiral Capital Co., Ltd)

- Yasuhiro Komatsu, Takaaki Nishii, Yo Honma, Akihiro Watanabe, and Reiko Kinoshita are candidates for Outside Directors as defined in Article 2-15 of the Companies Act.
- The Company will file Yasuhiro Komatsu, Takaaki Nishii, Yo Honma, Akihiro Watanabe, and Reiko Kinoshita as Independent Directors with the Tokyo Stock Exchange.
- Joseph Kenneth Keller is utilizing the abbreviated version of his name, Ken Keller, within the Company.

3. Changes to Audit & Supervisory Board Members

(1) Candidates for Audit & Supervisory Board Members

Name		Position (as of June 22, 2026)
Takashi Murata	New election	Outside Audit & Supervisory Board Member (Former Deputy Chief Cabinet Secretary for Crisis Management)
Sayuri Tago	New election	Outside Audit & Supervisory Board Member (Partner, Attorney-at-Law, Anderson Mori & Tomotsune)

- Upon the conclusion of the Company's 21st Ordinary General Shareholders Meeting on June 22, 2026, Yukiko Imazu and Mitsuhiro Matsumoto will retire as Audit & Supervisory Board Members due to the expiration of their term.
- Takashi Murata and Sayuri Tago are new candidates for Outside Audit & Supervisory Board Members as defined in Article 2-16 of the Companies Act.
- The Company will file Takashi Murata and Sayuri Tago as Independent Auditors with the Tokyo Stock Exchange.

For Reference: Incumbent Audit & Supervisory Board Members

Name	Position (as of June 22, 2026)
Miyuki Arai	Audit & Supervisory Board Member
Terumichi Yokoyama	Audit & Supervisory Board Member
Masako Watanabe	Outside Audit & Supervisory Board Member (Representative of Masako Watanabe Certified Public Accountant Office)

¹ Positions under the Global Management Structure of Daiichi Sankyo Group

² Holding concurrent position as the Unit Head under the Global Management Structure of Daiichi Sankyo Group

Attachment

1. Biographies of the Newly Appointed Representative Directors (As of February 26, 2026)

Takashi Matsumoto: Date of Birth February 6, 1964

Expected Date of Appointment: June 22, 2026

Number of Shares of the Company Held: 49 thousand (as of September 30, 2025)

Career Summary

Apr. 1987	Joined Daiichi Pharmaceutical Company, Limited
Apr. 2019	Vice President of Human Resources Department, General Affairs Division
Apr. 2021	Corporate Officer In charge of Human Resources, General Affairs
Apr. 2023	Executive Officer Head of Global HR ¹ (to present) CHRO (Chief Human Resources Officer) ¹ (to present)
Jun. 2024	Director, Executive Officer
Apr. 2025	Director, Senior Executive Officer (to present)

Shizuko Ueno: Date of Birth July 4, 1965

Expected Date of Appointment: June 22, 2026

Number of Shares of the Company Held: 25 thousand (as of September 30, 2025)

Career Summary

Apr. 1990	Joined Suntory Limited (currently Suntory Holdings Limited)
Dec. 2002	Transferred to Daiichi Suntory Pharma Co., Ltd.
Apr. 2010	Transferred to Daiichi Sankyo Company, Limited Temporary Transfer to Daiichi Sankyo RD Associe Co., Ltd.
Apr. 2020	Vice President of Clinical Development Dept. III, Development Function, R&D Division
Apr. 2022	Corporate Officer Head of Medical Affairs Division, Japan Business Unit
Apr. 2024	Executive Officer Head of Medical Affairs Division, Japan Business Unit Special Assignment on Patient Centricity (to present)
Apr. 2025	Executive Officer Head of Japan Business Unit ² and Head of Medical Affairs Division, Japan Business Unit (to present)
Jun. 2025	Director, Executive Officer (to present)

- The name on the family register of Shizuko Ueno is Shizuko Urano.

¹ Positions under the Global Management Structure of Daiichi Sankyo Group

² Holding concurrent position as the Unit Head under the Global Management Structure of Daiichi Sankyo Group

2. Biography of the Newly Appointed Director (As of February 26, 2026)

Stuart Mackey

Current Positions Held:

Head of Global Business Development, Daiichi Sankyo Group¹
(Global Head of Business Development, Daiichi Sankyo, Inc.)

Career Summary

1999	Joined Amgen, Inc.
2008	Managing Partner of Amgen Ventures
2009	Joined Santaris Pharma (Current F. Hoffmann-La Roche Ltd.) Chief Business Officer
2011	Joined Amgen, Inc. Deputy General Manager, Biosimilars Division
Apr. 2013	Joined Daiichi Sankyo, Inc. Global Head of Business Development Executive Vice President, Business Development, Daiichi Sankyo, Inc.
Apr. 2023	Head of Global Business Development, Daiichi Sankyo Group ¹ (to Present) Global Head of Business Development, Daiichi Sankyo, Inc. (to Present)

¹ Position under the Global Management Structure of Daiichi Sankyo Group

3. Biographies of the Newly Appointed Audit & Supervisory Board Members (As of February 26, 2026)

Takashi Murata: Date of Birth June 4, 1961

Former Deputy Chief Cabinet Secretary for Crisis Management

Career Summary

- Apr. 1984 Entered the National Police Agency (hereinafter “NPA”)
- Feb. 2011 Chief, Okinawa Prefectural Police
- Jan. 2014 Director-General, Criminal Investigation Bureau, Tokyo Metropolitan Police
- Aug. 2015 Senior Councilor, Commissioner-General’s Secretariat, NPA
- Aug. 2016 Chief, Osaka Prefectural Police
- Jan. 2018 Director-General, Security Bureau, NPA
- Feb. 2019 Ambassador Extraordinary and Plenipotentiary, Embassy of Japan in the Republic of Finland
- Jan. 2022 Deputy Chief Cabinet Secretary for Crisis Management

Material concurrent positions

- None

Sayuri Tago: Date of Birth November 24, 1984

Current Position Held:

Partner, Attorney-at-Law, Anderson Mori & Tomotsune

Career Summary

- Jan. 2013 Joined Bingham Sakai Mimura Aizawa
- Apr. 2015 Joined Anderson Mori & Tomotsune, following firms’ integration
- Jan. 2023 Partner, Attorney-at-Law, Anderson Mori & Tomotsune (to present)

Material concurrent positions

- Partner, Attorney-at-Law, Anderson Mori & Tomotsune

For Reference:

Directors and Audit & Supervisory Board Members after the election at the Ordinary General Shareholders Meeting (as of June 22, 2026)

Name	Position
Hiroyuki Okuzawa	Representative Director, President and CEO
Takashi Matsumoto	Representative Director Senior Executive Officer Head of Global HR ¹ CHRO (Chief Human Resources Officer) ¹
Shizuko Ueno	Representative Director Senior Executive Officer Head of Japan Business Unit ² Special Assignment on Patient Centricity
Joseph Kenneth Keller ³	Director Head of Global Oncology Business ¹ Head of Oncology Business Unit ¹
Stuart Mackey ⁴	Director Head of Global Business Development ¹
Yasuhiro Komatsu	Outside Director
Takaaki Nishii	Outside Director
Yo Honma	Outside Director
Akihiro Watanabe	Outside Director
Reiko Kinoshita	Outside Director
Miyuki Arai	Audit & Supervisory Board Member
Terumichi Yokoyama	Audit & Supervisory Board Member
Masako Watanabe	Outside Audit & Supervisory Board Member
Takashi Murata	Outside Audit & Supervisory Board Member
Sayuri Tago	Outside Audit & Supervisory Board Member

¹ Positions under the Global Management Structure of Daiichi Sankyo Group

² Holding concurrent position as the Unit Head under the Global Management Structure of Daiichi Sankyo Group

³ Holding concurrent position as the President, Daiichi Sankyo U.S. Holdings, Inc. and President & CEO, Daiichi Sankyo, Inc.

⁴ Holding concurrent position as the Global Head of Business Development, Daiichi Sankyo Inc.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.